The peptide antibiotics market size is estimated to be USD 6,210.8 million in 2022 and is expected to witness a CAGR of 6.45% during the forecast period 2023-2033. The increasing instances of antibiotic resistance, rising need for peptide antibiotics in hospitals and clinics, escalating number of product launches and approvals, and rise in incidence of illnesses such as bloodstream infections, hospital-acquired infections, and bacterial skin infections are factors contributing to the market growth. However, adverse effects of peptide antibiotics are expected to hinder the growth.

Segmentation

By Disease

Based on Disease, the market is segregated into blood stream infections, skin infections, HABP/VABP, and others. In 2022, the skin infections segment held the highest market share owing to increasing occurrence of bacterial skin illnesses such as carcuncles, impetigo, cellulitis, furuncles, and others, and widespread product availability.

By Product Type

On the basis of product type, the market is bifurcated into non-ribosomal synthesized peptide antibiotics and ribosomal synthesized peptide antibiotics. In 2022, the non-ribosomal synthesized peptide antibiotics segment held the highest market share due to the increasing accessibility of antibiotics made through a non-ribosomal synthesis, and rising demand for antibiotics made without ribosomes.

By Distribution Channel

Based on distribution channel, the market is segregated into specialty clinics, hospitals, homecare, and others. In 2022, the hospitals segment held the highest market share owing to increasing bacterial skin infections and ocular infections, and surging rates of hospital-acquired infections, bloodstream infections, and extended hospital stay.

By Route of Administration

Based on route of administration, the market is categorized into topical, oral, parenteral, and others. In 2022, the parenteral segment held the highest market share due to the availability of a large number of peptide antibiotics in injectable form, efficiency, and better bioavailability from injectable peptide antibiotics.

Regional Markets

In 2022, North America region accounted for the highest revenue in the peptide antibiotics market and is expected to maintain its dominance during the forecast period. This is attributed to the well-established pharmaceutical business, a strong emphasis on research and development (R&D), significant R&D investments, and the prominence of top pharmaceutical corporations.

Competitor Insights

Some of the key players operating in the peptide antibiotics market are Abbott (US), AbbVie Inc (US), Allergan Plc )Ireland), Dr. Reddy’s Laboratories Ltd (India), Fresenius Kabi AG (Germany), GSK (UK), HENGRUI (USA), Lilly (US), Merck (US), Novartis AG (Switzerland), Pfizer (US), Sandoz International GmbH (Germany), Sanofi (France), and Teva Pharmaceutical Industries Ltd. (Israel).

This comprehensive research report focuses on the global and regional market size and forecasts of diverse segments including disease, product type, distribution channel and route of administration from 2023 to 2033.

Report Scope:

Segmentation: Peptide Antibiotics Market Report 2022 – 2033

Disease (Revenue, USD Million), 2022 – 2033

• Blood Stream Infections
• Skin Infections
• HABP/VABP
• Others

Product Type (Revenue, USD Million), 2022 – 2033

• Non-ribosomal Synthesized Peptide Antibiotics
• Ribosomal Synthesized Peptide Antibiotics

Distribution Channel (Revenue, USD Million), 2022 – 2033

• Specialty Clinics
• Hospitals
• Homecare
• Others

By Route of Administration (Revenue, USD Million), 2022 – 2033

• Topical
• Oral
• Parenteral
• Others

By Region (Revenue, USD Million), 2022 – 2033

• North America
  • U.S.
  • Canada
• Europe
  • Germany
  • France
  • UK
  • Spain
  • Italy
  • Rest of Europe
• Asia Pacific
  • China
  • Japan
  • India
  • Australia
  • South Korea
  • Rest of APAC
• Latin America
  • Brazil
  • Mexico
  • Argentina
  • Rest of LATAM
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • Rest of MEA